Similarly, in patients with SSc-ILD+, MMP-3, MMP-7, MMP-9, MMP-10, and TIMP-1 levels were not associated with antibody positivity status (anti-nuclear antibodies, anti-centromere antibodies and anti-topoisomerase I antibodies), ILD and CTD duration, received treatments (csDMARDs, bDMARDs, and vasodilators), or the presence of other SSc clinical characteristic (renal impairment, cardiac involvement, Raynaud’s phenomenon, esophageal dysfunction, calcinosis, and synovitis) (data not shown). This evidence concerns the gene MMP10 and systemic sclerosis.